Mounjaro vs. Zepbound: What Changed and What Didn't

When Eli Lilly launched Zepbound in late 2023, many people assumed it was a new drug. It is not. Zepbound and Mounjaro contain identical molecules at identical doses — the only thing that changed was the FDA-approved indication on the label. Understanding that distinction is the key to navigating coverage, cost, and access.

The same drug, two approvals

Mounjaro (tirzepatide) was approved by the FDA in May 2022 for the treatment of type 2 diabetes in adults. It improves blood sugar control and, as a meaningful secondary effect, produces substantial weight loss.

Zepbound (tirzepatide) was approved in November 2023 specifically for chronic weight management — in adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition. It is the weight-management label for the same compound.

Available doses are identical across both brands: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg weekly injections.

Why the label matters so much

Insurance formularies are built around FDA-approved indications, not ingredients. This creates a situation that feels arbitrary but has real financial consequences:

• A plan that covers Mounjaro for diabetes does not automatically cover Zepbound for weight management — even though the drug is identical.
• A plan that covers Zepbound for weight management may have different cost-sharing than it applies to Mounjaro.
• Medicare Part D covers Mounjaro for diabetes but historically has not covered weight-management drugs — which is why Zepbound's Medicare coverage has been limited despite containing the same active ingredient.

Which one should you ask for?

The answer depends on your situation:

• You have type 2 diabetes → Mounjaro is the on-label option. Your plan is more likely to cover it, and your prescriber can document the diabetes indication.
• You have obesity but not diabetes → Zepbound is the correctly indicated product. Coverage depends on your specific plan.
• You have both conditions → Your prescriber has flexibility. Discuss which label gives you better access under your insurance.
• You are paying cash or using telehealth → Compounded tirzepatide is available through many platforms at significantly lower cost than either brand. The active ingredient is the same regardless of which brand name it replaces.

Savings cards: separate programmes

Eli Lilly runs distinct savings card programmes for Mounjaro and Zepbound. Eligibility requirements and copay caps differ between the two — even though the underlying drug is the same. If you are on Mounjaro and switch to Zepbound, you need to enrol in the Zepbound programme separately. Check the official Lilly websites for current terms, as both programmes have been updated multiple times.

The practical bottom line

For most patients, the choice between Mounjaro and Zepbound is not about pharmacology — it is about which label your insurance will pay for. If both are equally covered, either works identically. If one is preferred or requires less prior authorisation, that is the one to pursue. Your prescriber and insurance coordinator are the right people to navigate this with, not the internet.

This is educational content. Drug selection, prescribing decisions, and insurance navigation should involve a licensed clinician and direct contact with your insurer.